Ritter Sport USA, Inc. Partners with ReposiTrak to Proactively Deliver Outbound Food Traceability Data to U.S. Retailers
'Our decision to improve product traceability was driven by our commitment to doing what's right for our customers – both retail partners and the shoppers they serve,' said Ralf Hilpuesch, CEO of Ritter Sport USA. 'ReposiTrak enables us to proactively deliver the most complete and accurate food traceability data through a single, centralized platform. This step reflects our dedication to food safety, product integrity and transparency in every chocolate square we produce.'
The ReposiTrak Traceability Network is the industry's largest and fastest-growing platform for food traceability, enabling seamless data sharing between suppliers and retailers without the need for additional hardware, software or manual effort. Ritter Sport will utilize the network to deliver traceability data to its U.S. retail partners for every outbound shipment – enhancing transparency and collaboration across the supply chain.
'Ritter Sport is leading by example,' said ReposiTrak Chairman and CEO Randy Fields. 'They're setting a precedent for food manufacturers around the world – taking on traceability because it's the right thing for their customers and because the FDA has signaled that the FTL will only grow from here. That's the kind of leadership that will shape the future of food traceability.'
Ritter Sport's decision to voluntarily share traceability data exemplifies a growing movement among food manufacturers to prioritize safety, build trust and modernize operations – regardless of regulatory mandates.
With this integration, Ritter Sport gains the ability to:
Share outbound traceability data with its current and future U.S. retail customers
Streamline supply chain communications and reduce response time in the event of a recall or investigation
Strengthen customer relationships through transparency and accountability
In addition to openly sharing traceability data with retailer partners, Ritter Sport is committed to sustainability and ethical sourcing across the entire supply chain, aiming to trace 100% of its cocoa back down to the farming organization by 2025.
To learn more about Ritter Sport, visit www.ritter-sport.com /en. For more information about the ReposiTrak Traceability Network, visit www.repositrak.com.
About Ritter Sport
Established in 1912, Ritter Sport is a fourth-generation, family-owned company known for its signature square-shaped German chocolate, quality ingredients, vibrant snap-open packaging and commitment to sustainability. Ritter Sport's mission is to do the right thing to create really good chocolate and is the first major chocolate bar manufacturer to source 100% certified cocoa through its El Cacao programs and farmer partnerships. To learn more about Ritter Sport, visit www.ritter-sport.com/en.
ReposiTrak (NYSE: TRAK) provides retailers, suppliers and wholesalers with a robust solution suite consisting of three product families: food traceability, compliance and risk management and supply chain solutions. ReposiTrak's integrated, cloud-based applications are supported by an unparalleled team of experts. For more information, please visit www.repositrak.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
27 minutes ago
- CNBC
Novo Nordisk's Wegovy receives FDA approval to treat serious liver disease
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its Wegovy drug means for sales, and much more.
Yahoo
an hour ago
- Yahoo
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Part 2 of the ESSENCE trial will continue with the expected readout in 2029. The approval marks a positive development for Novo Nordisk as the European company faces downward sales for its GLP-1 products due to slower-than-expected penetration of its branded GLP-1 treatments and persistent use of compounded GLP-1 alternatives. Novo Nordisk projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%. In May, Health Canada accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for MASH. In March 2024, the FDA approved a label expansion for Wegovy based on a supplemental New Drug Application for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval was based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. The findings from SELECT also showed that risk reductions in MACE were achieved in up to five years. In addition, the label was updated to include data from SELECT showing a risk reduction in cardiovascular death by 15% and a risk reduction of death from any cause by 19%, compared to placebo. In March 2024, Madrigal Pharmaceuticals Inc.'s (NASDAQ:MDGL) Rezdiffra (resmetirom) became the first FDA-approved treatment for patients with liver scarring due to fatty liver disease. The FDA granted accelerated approval, and continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials. Price Action: NVO shares climbed 7.14% to $56.15, up $3.74, in after-hours trading on Friday. Read Next:Photo by Tobias Arhelger via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Novo Nordisk Shares Rise on U.S. Approval of Wegovy for Liver Disease
Novo Nordisk (NVO, Financials) shares climbed nearly 5% Monday after the U.S. Food and Drug Administration granted accelerated approval for its weight-loss drug Wegovy to treat metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis. Warning! GuruFocus has detected 1 Warning Sign with NVO. The approval makes Wegovy the first GLP-1 therapy cleared for MASH, a progressive liver condition affecting about 5% of U.S. adults, according to the American Liver Foundation. The drug was approved for use alongside a reduced-calorie diet and increased physical activity. Novo Nordisk said the decision was supported by the first phase of its ESSENCE trial, which showed Wegovy patients had statistically significant improvements in liver fibrosis compared to placebo. About 63% of participants receiving Wegovy achieved resolution of steatohepatitis without worsening fibrosis, compared with 34% in the placebo group. More than one-third of Wegovy patients also saw improvement in fibrosis without worsening steatohepatitis, versus 22% on placebo. The second phase of the trial is expected in 2029. The company said Wegovy is immediately available in the U.S. for MASH. The only other FDA-approved treatment for the disease is Madrigal Pharmaceuticals' (MDGL, Financials) Rezdiffra, cleared in 2024. Novo Nordisk shares were up 5.46% in London trading as of 10:43 a.m. This article first appeared on GuruFocus.
